PCSK9 and atherosclerosis: A study of patients with ASCVD found that ~ 40% are prescribed high-intensity statins and < 5% are prescribed ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, leaving them at preventable increased residual risk [14].